Sean P. Nolan - 02 Jan 2024 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: Chief Executive Officer, Director
Signature: /s/ Kamran Alam, Attorney-in-Fact
Issuer symbol: TSHA
Transactions as of: 02 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 04 Jan 2024, 16:41:35 UTC
Previous filing: 18 Dec 2023
Next filing: 16 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TSHA	Common Stock	Award	$0	+1,184,688	+101255%	$0.000000	1,185,858	02 Jan 2024	Direct	F1
holding	TSHA	Common Stock						1,535,545	02 Jan 2024	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSHA	Employee Stock Option (right to buy)	Award	$0	+1,184,688		$0.000000	1,184,688	02 Jan 2024	Common Stock	1,184,688	$1.71	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.
F2	The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
F3	25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.